Evotec's 13.5% Goldman Stake Is Almost Entirely Derivatives — and RBC Just Halved Its Target
Published on 10/31/2026 at 19:01 | Editorial boerse-global.de
Evotec investors scanning this week's regulatory filings could easily misread the headline number. Goldman Sachs reported 13.51% of voting rights as of October 21 — but only 0.09% of that comes from actual shares. The remaining 13.41% sits in instruments. Treating the total as a direct equity stake of comparable size would conflate two distinct categories of mandatory disclosure.
The figure also marks a decline from a previously reported 13.56%. Read without the shares-versus-instruments distinction, that dip might look like a sale of stock. It isn't. What the filing primarily documents is how heavily the disclosed position is built on derivatives rather than outright holdings.
A Separate Corporate Disclosure, a Different Question
On the same Wednesday, Evotec published a new total of 177,948,497 voting rights, following a conditional capital increase effective October 20. The company cited the issuance of subscription shares as the trigger. This is a corporate-level figure about the total voting pool — not a statement about Goldman's position, and certainly no signal on operating performance. Keeping the two disclosures apart matters, since one measures the denominator and the other a single holder's exposure.
RBC Cuts the Target in Half, Keeps the Rating
The more consequential input for valuation came a day earlier. RBC lowered its price target on Evotec from €10 to €5 while leaving its "Outperform" rating in place — and simultaneously tagging the stock with "Speculative Risk." The two moves belong together: the broker retains a positive view but has sharply reduced the value it assigns, and the explicit risk flag is not neutralized by the unchanged recommendation. An Outperform rating paired with a halved target and a speculative-risk label is not an unqualified vote of confidence.
Should investors sell immediately? Or is it worth buying Evotec?
Shares fell 3.8% on Friday, closing at €2.80. The decline and the analyst action landed on the same trading day, though no source establishes a causal link between them.
The Loss Forecast Is the Real Yardstick
Separating market valuation from business performance is where the analysis gets interesting. Evotec has provisionally reported group revenue of roughly €465.0 million for the first nine months of 2026, with adjusted group EBITDA of about ?€42.8 million. The adjusted operating result thus remains in negative territory.
Those preliminary figures are an interim snapshot — not a substitute for the full release and accompanying business update scheduled for November 5, 2026, when a webcast and conference call will also take place. Investors eager to read a turnaround into individual metrics should hold that distinction firmly in mind.
Evotec at a turning point? This analysis reveals what investors need to know now.
For the full year 2026, Evotec confirmed revenue guidance of approximately €570 million to €610 million. The adjusted EBITDA outlook remains around ?€70 million to ?€105 million. On that earnings basis, the confirmed forecast still does not point to a move into profitability.
What November 5 Must Deliver
The gap between the share price and the analyst target is therefore not the decisive test. What counts is how Evotec explains its further business development and what it says about hitting the confirmed guidance. A positive stock recommendation and an operational recovery remain two separate things — and the voting-rights filings do nothing to replace that scrutiny.
Ad
Evotec Stock: New Analysis - 31 October
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
